Eli Lilly and Company

Other

John Joseph Masters

Michael Robert Wiley

Ying Kwong Yee

Gerald Floyd Smith

David Kent Herron

David Mendel

Jeffry Bernard Franciskovich

Valentine Joseph Klimkowski

Anne Louise Tebbe

Jason Scott Sawyer

Douglas Wade Beight

Robert T Shuman

Steven E Hall

James Howard Wikel

Jennifer Marie Tinsley

Leonard Crayton Weir

Trelia Joyce Craft

Theodore Goodson, Jr

Jeffrey Alan Kyle

Guy Milot

Sajan Joseph

Christopher William Murray

John Walter Liebeschuetz

Stephen Clinton Young

Stuart Donald Jones

Nicholas Paul Camp

William Alexander Wylie

Brian Morgan Watson

Scott Martin Sheehan

Angela Lynn Marquart

David Birenbaum Engel

Robert M Scarborough

Matthew Joseph Fisher

Peter Thaddeus Gallagher

Joseph A Jakubowski

Marta Maria Pi&ntilde;eiro-N&uacute;&ntilde;ez

Andrew Michael Ratz

Maria Ann Whatton

Magnus Wilhelm Walter

Manuel Javier Cases-Thomas

Peter Guzzo

Theo Schotten

Wolfgang Stenzel

Sandra Ann Filla

Leander Merritt

Michael Paal

Brian Michael Mathes

Serge Louis Boulet

Jeffrey Thomas Mullaney

Gerd Ruhter

Richard Edmund Rathmell

Kevin John Hudziak

Kenneth James Ruterbories

Victor Giulio Matassa

Anette Margareta Johansson

Rushad Eruch Karanjawala

Philip Parker Waid

Chad Nolan Wolfe

Michael John Mayer

Carl Penman Denny

Mark Stephen Smyth

Barry P Clark

Jeremy Gilmore

Ting Su

Christopher David Beadle

Graham Henry Timms

Virginia Ann Wood

Hélène Catherine Eugénie Rudyk

Marta Maria Pi&ntilde;eiro-Nu&ntilde;ez

Theodore Goodson, Junior

Leland O Weigel

Robin G Simmonds

Phillip John Morgan

Carlos Lamas-Peteira

Marta Maria Pineiro-Nunez

Simon James Richards

Andrew David Rimmer

Jared Harris Linebarger

Salvatore Donato Lepore

Helen Louise Haughton

Marta Maria Pinelro-Núnez

Ankush Baburao Argade

Amanda Jane Lyons

Guy Milet

Theodore Goodson Jr

Jeffrey Bernard Franciskovich

Gordon Iain Campbell

Teresa Man

Maria Ann (nee Fagan) Whatton

Sivi Ouwerkerk-Mahadevan

Helene Catherine Rudyk

Manuel J Eli Lilly And Company Ltd Cases-Thomas

Gordon Iain Eli Lilly And Company Ltd Campbell

Teresa Eli Lilly And Company Limited Man

Hélène CE Li Lilly And Company Ltd Rudyk

Magnus Wilhelm 2Eli Lilly And Company Ltd Walter

Theodore Junior Goodson

Ankush B Rigel Pharmaceuticals Inc Argade

This application relates to a compound of formula (I) (or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor. An example of a compound of formula (I) is (a). 

Aromatic ether derivatives useful as thrombin inhibitors

This application relates to a compound of formula (I) (or a pharmaceutically acceptable salt of the compound) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor. 

Antithrombotic diamides

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, which are useful for the inhibition of the uptake of one or more physiologically active monoamines (serotonin, norepinephrine, and dopamine).

3-Aminopyrrolidines as inhibitors of monoamine uptake

This application relates to a compound of formula I (or a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor (I). 

Antithrombotic ethers

This application relates to a compound of formula I (or a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor.

Antithrombotic aromatic ethers

This application relates to a compound of formula (I) (or a pharmaceutically acceptable salt thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor. 

Substituted heterocyclic carboxamides with antithrombotic activity

3-aminopiperidines and 3-aminoquinuclidines as inhibitors of monoamine uptake

Compounds of the general formula (I) are inhibitors of the reuptake of norepinephrine. As such, they may be useful for the treatment of disorders of the central and/or peripheral nervous system. 

Morpholine derivatives as norepinephrine reuptake inhibitors

There is provided a compound of formula (I) wherein A is selected from &#x2014;O&#x2014; and &#x2014;S&#x2014;; X is selected from C-Calkyl, C-Calkenyl, C-Ccycloalkyl and C-Ccycloalkylalkyl, each of which may be optionally substituted with up to 3 substituents each independently selected from halo, C-Calkyl, C-Calkoxy, C-Calkyl-S(O)&#x2014; where n is 0, 1 or 2, &#x2014;CF, &#x2014;CN and &#x2014;CONH; Y is selected from phenyl, naphthyl, dihydrobenzothienyl, benzothiazolyl, benzoisothiazolyl, quinolyl, isoquinolyl, naphthyridyl, thienopyridyl, indanyl, 1,3-benzodioxolyl, benzothienyl, indolyl and benzofuranyl, each of which may be optionally substituted with up to 4 or, where possible, 5 substituents each independently selected from halo, C-Calkyl, C-Calkoxy, C-Calkyl-S(O)&#x2014; where n is 0, 1 or 2, nitro, acetyl, &#x2014;CF, &#x2014;SCFand cyano; and when Y is indolyl it may be substituted or further substituted by an N-substituent selected from C-Calkyl; Z is selected from H, ORor F, wherein Ris selected from H, C-Calkyl and phenyl C-Calkyl; Rand Rare each independently H or C-Calkyl; with the proviso that, when Z is H, then Y may not be optionally substituted phenyl or optionally substituted naphthyl. 

3-aryloxy/thio-3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake

There is provided a compound of formula (I) wherein A is selected from &#x2014;O&#x2014; and &#x2014;S&#x2014;; X is selected from phenyl optionally substituted with up to 5 substituents each independently selected from halo, C-Calkyl and C-Calkoxy, thienyl optionally substituted with up to 3 substituents each independently selected from halo and C-Calkyl, and C-Calkyl, C-Calkenyl, C-Ccycloalkyl and C-Ccycloalkylalkyl, each of which may be optionally substituted with up to 3 substituents each independently selected from halo, C-Calkyl, C-Calkoxy, C-Calkyl-S(O)&#x2014; where n is 0, 1 or 2, &#x2014;CF, &#x2014;CN and &#x2014;CONH; Y is selected from phenyl, naphthyl, dihydrobenzothienyl, benzothiazolyl, benzoisothiazolyl, quinolyl, isoquinolyl, naphthyridyl, thienopyridyl, indanyl, 1,3-benzodioxolyl, benzothienyl, indolyl and benzofuranyl, each of which may be optionally substituted with up to 4 or, where possible, up to 5 substituents each independently selected from halo, C-Calkyl, C-Calkoxy, C-Calkyl-S(O)&#x2014; where n is 0, 1 or 2, nitro, acetyl, &#x2014;CF, &#x2014;SCFand cyano; and when Y is indolyl it may be substituted or further substituted by an N-substituent selected from C-Calkyl; Z is selected from ORor F, wherein Ris selected from H, C-Calkyl and phenyl C-Calkyl; Rand Rare each independently H or C-Calkyl; and pharmaceutically acceptable salts thereof with the proviso that when Y is optionally substituted phenyl or optionally substituted 1,3-benzodioxolyl and Z is ORand X is optionally substituted phenyl then A is &#x2014;S&#x2014;. 

3-aryloxy/thio-2,3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake

There is provided a heretoaryloxy/thio 3-substituted propanamine compound of formula (I) wherein A is selected from &#x2014;O&#x2014; and &#x2014;S&#x2014;; X is selected from phenyl optionally substituted with up to 5 substituents each independently selected from halo, C-Calkyl and C-Calkoxy, thienyl optionally substituted with up to 3 substituents each independently selected from halo and C-Calkyl, and C-Calkyl, C-Calkenyl, C-Ccycloalkyl and C-Ccycloalkylalkyl, each of which may be optionally substituted with up to 3 substituents each independently selected from halo, C-Calkyl, C-Calkoxy, C-Calkyl &#x2014;S(O)&#x2014; where n is 0, 1 or 2, &#x2014;CF, &#x2014;CN and &#x2014;CONH; Y is selected from dihydrobenzothienyl, benzothiazolyl, benzoisothiazolyl, quinolyl, isoquinolyl, naphthyridyl, and thienopyridyl, each of which may be optionally substituted with up to 4 or, where possible, up to 5 substituents each independently selected from halo, C-Calkyl, C-Calkoxy, C-Calkyl-S(O)&#x2014; where n is 0, 1 or 2, nitro acetyl, &#x2014;CF, &#x2014;SCFand cyano; Z is selected from H, ORor F, wherein Ris selected from H, C-Calkyl and phenyl CCalkyl; Rand Rare each independently H or C-Calkyl; and pharmaceutically acceptable salts thereof. 

Propanamine derivatives as serotonin and norepinephrine reuptake inhibitors

Aryl and heteroaryl morpholine derivatives

Compounds of formula (I) in which R, X, Y, Cy, L and Lp(D)have the meanings given in the specification, are inhibitors of the serine protease, Factor Xa and are useful in the treatment of cardiovascular disorders.

Serine protease inhibitors

This application relates to a compound of formula I (or a pharmaceutically acceptable salt thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.

Substituted carboxamides

This application relates to a compound of formula (I) (or a pharmaceutically acceptable salt thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.

Substituted heterocyclic amides

Growing community of inventors

Fishers, IN, United States of America

John Joseph Masters